A Phase 1 interventional study of Cortexolone 17α-propionate solution and Placebo in Healthy Volunteers, sponsored by Cassiopea SpA. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-04.
Sponsored by Cassiopea SpA · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomised, double blind placebo controlled Phase I study which will assess the safety, tolerability and PK of Cortexolone 17α-propionate (and its metabolites), and its effects on the QTc interval when administered as multiple doses to healthy adult volunteers. Volunteers will receive a morning and evening dose (12 hours apart) of 225 mg (3 mL Cortexolone 17α-propionate applied topically as a 7.5 % solution (75 mg in 1 mL), giving a total daily dose of 450 mg (6 mL) per individual.
Thirty-two volunteers will be enrolled and evaluated (i.e. complete the study). Subjects will be dosed in four groups of eight (purely for logistical reasons relating to the procedure times expected with dosing and ECG). Volunteers will receive either the active drug or matching placebo in a 3:1 ratio. Therefore within each cohort, six volunteers will receive the active drug and two will receive matching placebo.
Volunteers will be screened within 20 days prior to entering the study on Day -1. Each volunteer will receive verbal and written information followed by signing of the ICF prior to any screening procedures taking place. Volunteers will be admitted to the study unit on Day -1, dosed twice daily on Days 1-3 and once on Day 4 (morning dose only). They will be discharged on Day 6 and will have a telephone follow-up on Day 14. If they report any relevant Adverse Event (AE) they will be invited to attend the unit for an outpatient visit as close to Day 14 as is possible.
Cassiopea SpA is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects who are either: (a) Non-, e.g. (as defined as amenorrhoea for at least 12 months with no alternative medical cause) or permanently sterile (permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy) OR (b) Childbearing potential AND (if heterosexually active) agree to use at least one form of highly effective as defined below, starting at least one menstrual cycle before first study drug administration and continuing until at least 3 months after the end of the systemic exposure of the study drug.
Highly effective contraceptive methods for females are as follows:
Combined (oestrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation as follows:
Progestogen-only hormonal contraception associated with inhibition of ovulation as follows: o Oral
Male subjects, if heterosexually active and with a female partner of childbearing potential or a pregnant or breastfeeding partner, must agree to use barrier contraception (male condom) for the treatment period and for at least three months after the end of the systemic exposure of the study drug. Female partners of male subjects who are of childbearing potential must use one or more forms of highly effective contraception as defined above, starting at least one menstrual cycle before (their male subject's) first study drug administration and continuing until at least three months after the end of their male partner's systemic exposure to the study drug.
For male subjects who have had a vasectomy (with documented evidence of azoospermia if possible) and agree to use a barrier method (male condom) for the stated time period, no additional contraceptive method is required by their female partner.
Exclusion Criteria:
Any clinically significant abnormalities in rhythm, conduction or morphology of resting or clinically important abnormalities that may interfere with the interpretation of QTc interval changes. This includes subjects with any of the following (at screening, Day -1 or pre-dose of Day 1):
Subjects with borderline abnormalities may be included if the deviations do not pose a safety risk, and if agreed between the appointed Cardiologist and the investigator.
Has vital signs outside of the following normal range at screening, Day -1 or Day 1 predose:
Blood pressure (BP):
Supine BP (after at least 5 minutes of supine rest):
Has a mental incapacity or language barriers precluding adequate understanding, co-operation, and compliance with the study requirements.
Cassiopea S.p.A. CONFIDENTIAL 30 April 2018 Protocol Ref: CB-03-01/33 Final Version 5.0 Page 30 of 43 RPL Study No. C16021 C16021_Protocol_v5.0_30Apr2018
Subjects with any medical history, conditions, or risks that, in the opinion of the investigator, may interfere with the subject's full participation in the study or compliance with the protocol, or may pose any additional risk for the subject or confound the assessment of the subject or outcome of the study.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Cortexolone 17α-propionate solution
Drug: Placebo
Single topical application to be applied twice daily (0 hour and 12 hour) on Days 1-3 and Once Daily (0 hour) on Day 4.
matching placebo
PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)
Cmax: Maximum observed plasma concentration Days 1 and 4
Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.
PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)
tmax: Time of maximum observed plasma concentration
Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.
PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)
t½: Apparent plasma terminal elimination half-life
Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.
PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)
AUC0-24h: Area under the plasma concentration-time curve from time zero to 24 hours, calculated by the linear/log trapezoidal rule
Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.
PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)
AUC0-t: Area under the plasma concentration-time curve from time zero up to the last quantifiable concentration
Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.
PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)
AUC0-inf: Area under the plasma concentration-time curve from time zero to infinity
Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.
PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)
CL: Blood clearance
Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.
PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)
λz: Terminal elimination rate constant
Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.
PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)
CLr: Renal clearance
Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.
PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)
Vz: Volume of distribution
Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.
PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)
MRT: Mean residence time
Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.
QT interval changes
QT intervals will be assessed using triplicate 12-lead ECGs electronically recorded at each time point and evaluated by a blinded select cardiologist
Time frame: Day1 (each hour starting from 2 till 12 hours post IMP administration), Day 4 (each hour starting from 2 till 12 hours post IMP administration), Day 5 (24 hs post last IMP administration) and Day 6 (48 hs post last IMP administration).
Incidence of treatment-emergent adverse event
Time frame: Day1, 2, 3, 4, 5, 6 and 14
Proportion of subjects with skin reaction
Skin reactions at the site of application will be assessed using a standardised in-house method. Any pain will be assessed using a Visual Analogue Scale (O-10).
Time frame: Day1, 2, 3, 4, 5, 6 and 14 (if applicable)
Proportion of subjects with clinically significant changes in laboratory safety tests (haematology, chemistry, coagulation and urinalysis)
Time frame: Haematology, chemistry and coagulation: Day-1/1, 3, 5 and 14. Urinalysis: Day-1 and Day 14
Proportion of subjects with abnormalities on electrocardiogram (ECG)
Time frame: Day1, 4, 6 and 14
Proportion of subjects with clinically significant changes in vital signs (systolic blood pressure, diastolic blood pressure, pulse rate and temperature)
Time frame: Day1, 2, 3, 4, 5 and 14
Ran from Jun 2018 to primary completion in Sep 2018, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clascoterone
Cassiopea SpA